Aa
rep9 ac at euro liver meeting
this is the only drug the cures hbv:
Oral Presentations
Session Title: Parallel Session: HEPATITIS B
Presentation Date: 01 APR, 2011
REP 9AC IS A POTENT HBSAG RELEASE INHIBITOR WHICH CLEARS SERUM HBSAG AND ELICITS SVRS IN PATIENTS WITH CHRONIC HEPATITIS B
M. Al-Mahtab1, M. Bazinet2, A. Vaillant2*
1Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, 2REPLICor Inc., Montreal, QC, Canada. ****@****
Background: HBsAg plays a role in suppressing the immune system and may allow maintenance of chronic liver infection. REP 9AC inhibits the release of HBsAg from infected hepatocytes. In preclinical studies surface antigen seroclearance occurred after two weeks of treatment and four weeks of treatment resulted in 55% of animals achieving a durable SVR. REP 9AC is currently being evaluated in patients with chronic HBV in a proof of concept clinical trial. An updated report on interim clinical trial data will be presented.
Methods: Patients were HBsAg+ with pre-treatment HBV DNA titers between 106 and 1012 copies/ml and had significant liver fibrosis. Safety and virologic response (HBV DNA, HBsAg, anti-HBs) were assessed at the trial site and by confirmatory testing (HBsAg, HBeAg, anti-HBs, anti-HBe) of frozen serum samples using the Architect ™ testing platform.
Results: At the time of abstract submission, 5 of 8 patients treated have cleared serum HBsAg as early as 7 days and no later than 15 weeks following initiation of treatment at higher doses. Anti-HBsAg antibodies have been observed in 7 out of 8 patients. Six, patients have achieved a 3 to 7 log reduction in their HBV DNA titers from pre-treatment levels after 7-13 weeks of treatment and three of these patients have achieved complete control of their infection after 20-27 weeks of treatment (HBV DNA -, HBsAg -, HBeAg -, anti-HBs +, anti-HBe +) and are being followed off treatment. These 3 patients are currently maintaining control over their infections 14, 27 and 52 weeks after stopping treatment.
Conclusions: REP 9AC can rapidly clear serum HBsAg in infected patients which appears to allow the restoration of an effective immune response, leading to the achievement of SVRs in three patients to date. These results suggest that REP 9AC may become an important new tool in the treatment of chronic hepatitis B.
Oral Presentations
Session Title: Parallel Session: HEPATITIS B
Presentation Date: 01 APR, 2011
REP 9AC IS A POTENT HBSAG RELEASE INHIBITOR WHICH CLEARS SERUM HBSAG AND ELICITS SVRS IN PATIENTS WITH CHRONIC HEPATITIS B
M. Al-Mahtab1, M. Bazinet2, A. Vaillant2*
1Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, 2REPLICor Inc., Montreal, QC, Canada. ****@****
Background: HBsAg plays a role in suppressing the immune system and may allow maintenance of chronic liver infection. REP 9AC inhibits the release of HBsAg from infected hepatocytes. In preclinical studies surface antigen seroclearance occurred after two weeks of treatment and four weeks of treatment resulted in 55% of animals achieving a durable SVR. REP 9AC is currently being evaluated in patients with chronic HBV in a proof of concept clinical trial. An updated report on interim clinical trial data will be presented.
Methods: Patients were HBsAg+ with pre-treatment HBV DNA titers between 106 and 1012 copies/ml and had significant liver fibrosis. Safety and virologic response (HBV DNA, HBsAg, anti-HBs) were assessed at the trial site and by confirmatory testing (HBsAg, HBeAg, anti-HBs, anti-HBe) of frozen serum samples using the Architect ™ testing platform.
Results: At the time of abstract submission, 5 of 8 patients treated have cleared serum HBsAg as early as 7 days and no later than 15 weeks following initiation of treatment at higher doses. Anti-HBsAg antibodies have been observed in 7 out of 8 patients. Six, patients have achieved a 3 to 7 log reduction in their HBV DNA titers from pre-treatment levels after 7-13 weeks of treatment and three of these patients have achieved complete control of their infection after 20-27 weeks of treatment (HBV DNA -, HBsAg -, HBeAg -, anti-HBs +, anti-HBe +) and are being followed off treatment. These 3 patients are currently maintaining control over their infections 14, 27 and 52 weeks after stopping treatment.
Conclusions: REP 9AC can rapidly clear serum HBsAg in infected patients which appears to allow the restoration of an effective immune response, leading to the achievement of SVRs in three patients to date. These results suggest that REP 9AC may become an important new tool in the treatment of chronic hepatitis B.
I am sure I had searched the EASL program for REP9AC and found nothing. I would like to post this on the Chinese forum, if you don't mind.
But there is nothing new in the oral presentation! It wasn't even mentioned on Replicor website.
But there is nothing new in the oral presentation! It wasn't even mentioned on Replicor website.
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
